News Search Results
Oct 27, 2025, 01:00 ET EU Climate Ambitions at Risk Flawed Regulatory Framework Threatens Shipping Innovation
greater involvement of all stakeholders. About I-Tech AB I-Tech is a biotechnology company that has developed the antifouling technology Selektope®, an active substance that prevents barnacle attachment on submerged surfaces such
More news about: I-Tech
Oct 26, 2025, 23:20 ET CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit
More news about: CSL
Oct 26, 2025, 22:30 ET CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit
More news about: CSL
Oct 26, 2025, 07:42 ET STARS OF SCIENCE CROWNS SEASON 17 WINNER
levels and helps users take preventive action before mental health symptoms arise. Dardabou's invention impressed judges for its potential to blend biotechnology with emotional well-being, addressing a global challenge through accessible, everyday technology. Upon being named the winner,
More news about: Stars of Science
Oct 24, 2025, 16:01 ET Innocan Pharma to Present at the 2025 ThinkEquity Conference
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking place October 30, 2025, at the Mandarin Oriental,
More news about: Innocan Pharma Corporation
Oct 24, 2025, 16:01 ET Innocan Pharma to Present at the 2025 ThinkEquity Conference
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking place October 30, 2025, at the Mandarin Oriental,
More news about: Innocan Pharma Corporation
Oct 24, 2025, 13:45 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
The litigation is focused on the propriety of MoonLake's statements about the trial design and data for SLK. The clinical stage biotechnology company is focused on skin inflammatory diseases driven by a cytokines known as IL-17A and IL-17F. Central to SLK's commercial
More news about: Hagens Berman Sobol Shapiro LLP
Oct 24, 2025, 12:30 ET Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent")
More news about: Northwest Biotherapeutics, Inc.
Oct 24, 2025, 12:17 ET Three Rubin Rudman Partners Named to 2026 Lawdragon 500 Leading Dealmakers in America
family-owned business across a broad range of industries including construction, financial services, real estate, manufacturing, distribution, biotechnology, health care, and hospitality. With over 20 years of experience, including more than three years as the leader of the firm's Corporate group, Cordes
More news about: Rubin Rudman
Oct 24, 2025, 12:03 ET Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent")
More news about: Northwest Biotherapeutics, Inc.
Oct 24, 2025, 08:30 ET Maximum Fair Price Strategies for IPAY2027 Readiness, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 24, 2025, 08:30 ET Lilly to Acquire Adverum Biotechnologies
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 24, 2025, 08:16 ET BiomEdit Awarded Nearly $2 Million from Bezos Earth Fund to Advance AI Model for Methane-Reduction Strategies in Cattle
Oct. 24, 2025 /PRNewswire/ -- In partnership with Bioversity International USA and Yale University, BiomEdit, a pioneering animal health biotechnology company, announced today it has been selected as one of 15 global teams awarded funding of nearly $2 million from the Bezos Earth Fund's
More news about: BiomEdit
Oct 24, 2025, 08:00 ET Orna Therapeutics Announces Encore Presentation at the American College of Rheumatology Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
WATERTOWN, Mass., Oct. 24, 2025 /PRNewswire/ -- Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced
More news about: Orna Therapeutics
Oct 24, 2025, 07:00 ET Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations
authorization allows Origin to participate in China's rapidly evolving GMO seed sector, positioning the Company to capitalize on the increasing adoption of biotechnology in agriculture. Each specific GMO crop will continue to require individual registration and approval prior to commercialization.
More news about: Origin Agritech Limited
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies, today presented new results from its ongoing Phase 1 study of HCB101, a novel SIRPα-engineered
More news about: HanchorBio Inc.
Oct 23, 2025, 16:58 ET CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment
SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled
More news about: CAGE Bio Inc.
Oct 23, 2025, 16:05 ET INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
(NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside
More news about: INOVIO Pharmaceuticals, Inc.
Oct 23, 2025, 16:05 ET Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
diseases, today announced that it has earned the highest ranking in Science's 2025 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the companies with the best reputations as employers. "It is an incredible
More news about: Insmed Incorporated
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
Mass., Oct. 23, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to zenocutuzumab-zbco
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 12:00 ET Czech Breakthrough in Medicine: H₂ Global Group Receives Regulatory Approval for Hydrogen Clinical Study -- New Era in Alzheimer's Therapy Begins
This milestone marks a historic achievement for Czech and European biotechnology, as it represents Europe's first fully approved clinical trial investigating non-invasive hydrogen inhalation as a neuroprotective therapy.
More news about: H2 Global Group
Oct 23, 2025, 11:52 ET Osmolality as a Key to Diagnosing Diabetes Insipidus, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 11:00 ET Medical Device Market Surges to USD 750 Billion by 2033, Propelled by 5.5% CAGR - Verified Market Reports®
Device Market The next generation of medical devices is defined by cross-domain innovation—merging biotechnology, materials engineering, and artificial intelligence. Smart implants capable of wireless communication are now used for continuous patient monitoring,
More news about: Verified Market Reports